61111327aa40346ca988959a e2112-randomized-phase-iii-trial-of-endocrine-therapy-plus-entinostat-or-placebo-in-hormone-receptor-positive-advanced-breast-cancer-a-trial-of-the-ecog-acrin-cancer-research-group 2021-08-09T11:36:36.479Z 5e283dc83b5e750642253bfc 8f13726e-5635-471f-ad3c-fc910a6ac2b1 mas_evidence_types:Randomised%20controlled%20trials Primary research RCT (n=608) found addition of entinostat to exemestane did not improve progression free survival (3.3 vs 3.1 months; HR= 0.87; 95% CI, 0.67 to 1.13) or overall survival (23.4 vs 21.7 months; HR= 0.99; 95% CI, 0.82 to 1.21), vs exemestane alone. <p>Entinostat is a histone deacetylase inhibitors.&nbsp; Investigation on the use of this agent in breast cancer has now been abdandoned by the manufacturer following the results of this study.</p> https://www.medicinesresources.nhs.uk/e2112-randomized-phase-iii-trial-of-endocrine-therapy-plus-entinostat-or-placebo-in-hormone-receptor-positive-advanced-breast-cancer-a-trial-of-the-ecog-acrin-cancer-research-group.html https://ascopubs.org/doi/full/10.1200/JCO.21.00944 2021-08-06T00:00:00Z 2021-08-09T11:36:07.144Z